Journal: Cancer treatment reviews

Article Title: In vivo cancer vaccination: which dendritic cells to target and how?

doi: 10.1016/j.ctrv.2018.10.012

Figure Lengend Snippet: Use of TLR7 agonists as adjuvant in active clinical trials (* www.clinicaltrials.gov ).

Article Snippet: 3 , NCT03416335 A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile , Neoplasms (44) , • TLR7 agonist-DSP-0509 , • Phase I, single group assignment and open- label. , • Recruiting. • Start date: 1st June 2018 • Completion date: July 2020 , • Boston Biomedical, Inc • Syneos Health.

Techniques: Adjuvant, Clinical Proteomics, Labeling

Journal: Cancer treatment reviews

Article Title: In vivo cancer vaccination: which dendritic cells to target and how?

doi: 10.1016/j.ctrv.2018.10.012

Figure Lengend Snippet: Use of TLR3 agonists as adjuvant in a selection of active clinical trials (* www.clinicaltrials.gov ).

Article Snippet: 3 , NCT03416335 A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile , Neoplasms (44) , • TLR7 agonist-DSP-0509 , • Phase I, single group assignment and open- label. , • Recruiting. • Start date: 1st June 2018 • Completion date: July 2020 , • Boston Biomedical, Inc • Syneos Health.

Techniques: Adjuvant, Selection, Clinical Proteomics, In Situ, Activity Assay, Immunofluorescence, Recombinant, Immunopeptidomics, Labeling

Journal: Oncotarget

Article Title: Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells

doi: 10.18632/oncotarget.11618

Figure Lengend Snippet: CLL cells from 10 patients were purified and cultured in the presence (2S) or absence (unstimulated (US)) of IL-2 and resiquimod with or without (control, CTR) dexamethasone (30 μM, DEX) in serum free media. a. Cells were stained with 7AAD 48 h after DEX treatment and analyzed by flow cytometry. Specific death (i.e. the difference between the percentages of 7AAD − cells in the control and DEX treated samples) and median forward scatter (mfi) (indicating cell size) for individual patient samples are shown on the left and right panels, respectively. b. mRNA levels of PPARA (left) and PDK4 (right) (relative to HPRT) were determined by quantitative PCR in 20 different samples 18 h after treatment. c. Immunoblots of Ser211 phosphorylated glucocorticoid receptor (P-GR) in unstimulated CLL cells (−) and 2S-stimulated cells (+) with and without dexamethasone (DEX) treatment. Protein lysates for patient cells were collected 18 h after DEX treatment and immunoblots were probed with antibodies to pGR and actin used as a loading control. Representative results for patients P5, P6 and P7 are shown. *, p < .05; **, p < .01; ns, not significant.

Article Snippet: Resiquimod (TLR-7/8 agonist) was from Alexis Biochemicals (San Diego, CA).

Techniques: Purification, Cell Culture, Staining, Flow Cytometry, Real-time Polymerase Chain Reaction, Western Blot

Journal: Oncotarget

Article Title: Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells

doi: 10.18632/oncotarget.11618

Figure Lengend Snippet: Purified CLL cells were stimulated with IL2 and Resiquimod in the presence or absence of dexamethasone (30 μM) or ruxolitinib (0.5 μM). a. Size changes of viable 7AAD- cells (median of forward scatter parameter (mfi)) were determined by flow cytometry after 48 h. Decreased size due to activation in the presence of ruxolitinib (RUX) is indicated for each patient sample by the lines. b. After 48 h, levels of TNFα (left panel, n = 5) and IL10 (right panel, n = 11) in the culture supernatants of 2S cells in the presence and absence (CTR) of RUX were measured by ELISAs. c. After 48 h, specific death was calculated from the difference between the percentages of 7AAD- cells in control and DEX-treated samples 48 h after RUX treatment ( n = 12). d. Changes in circulating lymphocytes (WBC) as a measure of clinical response are shown for 3 patients 1 month after treatment with high-dose glucocorticoids in the presence or absence of Ruxolitinib at the doses indicated in the graphs. *, p < .05; **, p < .01.

Article Snippet: Resiquimod (TLR-7/8 agonist) was from Alexis Biochemicals (San Diego, CA).

Techniques: Purification, Flow Cytometry, Activation Assay

Journal: Oncotarget

Article Title: Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells

doi: 10.18632/oncotarget.11618

Figure Lengend Snippet: CLL cells were purified and cultured in the presence (2S) or absence (unstimulated (US)) of IL-2 and resiquimod with or without dexamethasone (DEX) (30 μM) and 2-deoxyglucose (2DG) (3mM). After 18 h, PKM2 a. and PDK4 d. transcripts (relative to HPRT) were measured by quantitative PCR. The lines indicate results obtained from samples from the same patient. b. After 48 h, flow cytometry was used to determine the size of viable 7AAD − cells by the median of the forward scatter parameter (mfi). c. After 18 h, phosphorylated and un-phosphorylated FOXO1 and AKT levels were measured by immunoblotting and quantified by densitometry. Circles indicate absence and black squares indicated presence of DEX treatment. An example is shown and relative densitometric values are plotted in the lower graphs, with results for individual patient samples ( n = 4 for AKT and n = 7 for FOXO1). e. Percentages of viable 7AAD − cells that exclude 7AAD were determined by flow cytometry after 48h. *, p < .05; **, p < .01.

Article Snippet: Resiquimod (TLR-7/8 agonist) was from Alexis Biochemicals (San Diego, CA).

Techniques: Purification, Cell Culture, Real-time Polymerase Chain Reaction, Flow Cytometry, Western Blot

Journal: Oncotarget

Article Title: Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells

doi: 10.18632/oncotarget.11618

Figure Lengend Snippet: a. 2S CLL cells were stimulated with IL2 and resiquimod and treated with or without dexamethasone (DEX) (30 μM) or ruxolitinib (RUX) or the combination of DEX and RUX, each in the presence and absence of idelalisib (IDE) or buparlisib (BKM). Protein lysates of 2S-stimulated cells were collected for immunoblotting 18 h after the treatments. A representative example of immunoblots for pSTAT3 and STAT3 is shown at the top of the graph. Results for pSTAT3 for 4 different patient samples were quantified by densitometry and normalized to actin as shown in the bottom panel. The horizontal lines represent mean values for the 4 samples. b. An example of flow cytometric analysis of cell death in 2S-stimulated cells in the absence (left) and presence (right) of ruxolitinib (2S+RUX) assessed by 7AAD staining is shown in the top dot-plots. The upper row (CTR) shows single agent treatment with IDE or BKM (0.5 μM each) while the lower row indicates respective treatments in the presence of DEX. The numbers in each dot-plot represent percentages of viable 7AAD − cells. Averages and standard errors for the indicated numbers of patient samples are shown in the bottom panel. *, p < 0.05.

Article Snippet: Resiquimod (TLR-7/8 agonist) was from Alexis Biochemicals (San Diego, CA).

Techniques: Western Blot, Staining

Journal: Fundamental Research

Article Title: SARS-CoV-2 virus: Vaccines in development

doi: 10.1016/j.fmre.2021.01.009

Figure Lengend Snippet: The development of vaccine candidates in clinical trial.

Article Snippet: , BBV152 , Bharat Biotech , India , Whole-virus inactivated , Aluminum hydroxide gel (Algel) or a novel TLR7/8 agonist adsorbed Algel (Algel-IMDG) , IM , 2 , Phase 1/2 NCT04471519 CTRI/2020/09/027674.

Techniques: Recombinant, Cell Stimulation, Plasmid Preparation, Binding Assay